RE:Reuters: Big Pharma will find right formula for M&A binge Fiercebiotech reported in December 2022 - " The biggest in life sciences so far for 2022 was in fact a medtech transaction: Johnson & Johnson’s buy of Abiomed, valued at nearly $19 billion, was announced in early November. Second on the list was the odd deal from Pfizer and Biohaven, which saw the pharma behemoth carve off the smaller company’s migraine franchise, leaving the pipeline where it is. Third was another one from deal-hungry Pfizer: the $5.5 billion acquisition of Global Blood Therapeutics." "The predictions heading into 2022 were for a busy year of deals as the top 18 pharma companies by market cap had an estimated $1.7 trillion to throw around. But it just didn't happen that way. Companies instead bit on smaller companies in the single-digit billions, with the odd number in the teens.
Now, pharma is heading into the new year with a bit less uncertainty: The U.S. midterm elections are settled, and the Inflation Reduction Act’s impact on pricing is more understood. There’s still plenty of corporate cash to go around, and many of the largest pharmas are in need of a refresh to their pipelines. That means 2023 has the potential to be an active year, according to PwC."
"Deals in the $5 billion to $15 billion range will continue to be the sweet spot, but PwC says the second half of 2023 could see some larger transactions. "
https://www.fiercebiotech.com/biotech/fewer-smaller-clearer-life-sciences-ma-values-halve-volumes-plunge-will-we-ever-see-deals